Novavax | NVAX - Debt


Novavax reported $233.31M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
Agenus USD 35.54M 2.34M Mar/2025
AstraZeneca USD 32.63B 207M Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Cassava Sciences USD 0 0 Dec/2024
Geron USD 121.92M 73K Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
MannKind USD 119.91M 73.09M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 734M 7M Sep/2025
Novartis USD 32.02B 615M Sep/2025
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 60.85B 78M Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025